Effects of intraoperative HES130/0.4 on postoperative kidney function :A retrospective cohort study using DPC database.

Effects of intraoperative HES130/0.4 on postoperative kidney function :A retrospective cohort study using DPC database. - Effects of HES130/0.4 on postoperative kidney function

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000027896

Enrollment

50000

Registered

2017-06-30

Start date

2017-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients who underwent surgery under general anesthesia or regional anesthesia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Patients who underwent surgery under general anesthesia or regional anesthesia from January 2014 to December 2016 (2)Patients 18 years or older (3)Patients with serum creatinine data within 30 days before surgery and within 7 days after surgery

Exclusion criteria

Exclusion criteria: (1)Patients who underwent dialysis treatment or end stage kidney disease (eGFR<15mL/min/1.73m2) before surgery (2)Patients who received dextran or HES70/0.5 (3)Patients who received HES130/0.4 or albumin or blood products during the period between 7 days before surgery and the day of surgery (4)Patients who died within 2 days after surgery (5)Patients who underwent multiple surgeries (during the period of 30 days before and 30 days after the surgery) (6)Patients who received HES130/0.4 only before and/or after surgery on the day of surgery

Design outcomes

Primary

Measure	Time frame
Incidence of postoperative acute kidney injury	—

Secondary

Measure	Time frame
(1)Incidence of each stage of KDIGO acute kidney injury classification after surgery (2)Percentage of patients receiving renal replacement therapy (within 21 days after surgery) (3)Duration of postoperative renal replacement therapy (4)Postoperative 30 day mortality (5)Length of postoperative hospital stay (6)Kidney function for the patients developing postoperative acute kidney injury (90 days after surgery) (7)Volume of administered IV solution (day of surgery) (8)Use of vasopressor (day of surgery) (9)Volume of blood products (day of surgery) (10)Coagulation status (platelet count, PT-INR, APTT)	—

Measure

Time frame

(1)Incidence of each stage of KDIGO acute kidney injury classification after surgery (2)Percentage of patients receiving renal replacement therapy (within 21 days after surgery) (3)Duration of postoperative renal replacement therapy (4)Postoperative 30 day mortality (5)Length of postoperative hospital stay (6)Kidney function for the patients developing postoperative acute kidney injury (90 days after surgery) (7)Volume of administered IV solution (day of surgery) (8)Use of vasopressor (day of surgery) (9)Volume of blood products (day of surgery) (10)Coagulation status (platelet count, PT-INR, APTT)

—

Countries

Japan

Contacts

Public ContactSatoru Kamoshita

Otsuka Pharmaceutical Factory, Inc. Applied Clinical Development Department

kamoshitas@otsuka.jp03-5217-5954

Outcome results